PA
VNDA icon

PharVision Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History

PharVision Advisers’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-57,037
Closed -$285K – 1028
2025
Q3 		$285K Buy
+57,037
New +$264K 0.16% 258

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

PharVision Advisers's VNDA Position: Q4 2025 in Review

PharVision Advisers sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 57,037 shares — an estimated $285K sold.

PharVision Advisers first reported a position in VNDA in Q3 2025 and held it in 1 quarter. The position peaked at $285K in Q3 2025. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

  • PharVision Advisers reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 57,037 Vanda Pharmaceuticals shares in Q4 2025, an estimated $285K.
  • PharVision Advisers first reported a position in Vanda Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Vanda Pharmaceuticals position peaked at $285K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.